{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:41:17Z","timestamp":1793018477605,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10-11","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005242","name":"Heed Ophthalmic Foundation","doi-asserted-by":"publisher","award":["Heed Fellowship Award"],"award-info":[{"award-number":["Heed Fellowship Award"]}],"id":[{"id":"10.13039\/100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","award":["CD-NMT-0714-0648"],"award-info":[{"award-number":["CD-NMT-0714-0648"]}],"id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K08EY026650"],"award-info":[{"award-number":["K08EY026650"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY010572"],"award-info":[{"award-number":["P30EY010572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Unrestricted grant to the Casey Eye Institute Department of Ophthalmology"],"award-info":[{"award-number":["Unrestricted grant to the Casey Eye Institute Department of Ophthalmology"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41434-021-00294-2","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T02:02:58Z","timestamp":1632794578000},"page":"601-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Injection pressure levels for creating blebs during subretinal gene therapy"],"prefix":"10.1038","volume":"29","author":[{"given":"Brittni A.","family":"Scruggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-3188","authenticated-orcid":false,"suffix":"Jr.","given":"Huber Martins","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5770-279X","authenticated-orcid":false,"given":"Mariana","family":"Matioli da Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Kogachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Pennesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-9030","authenticated-orcid":false,"given":"Andreas K.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"294_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman J, Chung D, Yu Z, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(17)31868-8","journal-title":"Lancet."},{"key":"294_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, Nanda A, Davies A, Wood L, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26:354\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0763-1","journal-title":"Nat Med"},{"key":"294_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","volume":"137","author":"M Fischer","year":"2019","unstructured":"Fischer M, Ochakovski G, Beier B, Seitz I, Vaheb Y, Kortuem C, et al. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial. JAMA Ophthalmol. 2019;137:1247\u201354. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.3278","journal-title":"JAMA Ophthalmol"},{"key":"294_CR4","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","volume":"26","author":"C Cukras","year":"2018","unstructured":"Cukras C, Wiley H, Jeffrey B, Sen H, Turriff A, Zeng Y, et al. Retinal AAV8-RS1 gene therapy for X-Linked retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery. Mol Ther. 2018;26:2282\u201394. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.025","journal-title":"Mol Ther"},{"key":"294_CR5","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"R MacLaren","year":"2014","unstructured":"MacLaren R, Groppe M, Barnard A, Cottriall C, Tolmachova T, Seymour L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet. 2014;383:1129\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(13)62117-0","journal-title":"Lancet."},{"key":"294_CR6","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","volume":"39","author":"J Davis","year":"2019","unstructured":"Davis J, Gregori N, MacLaren R, Lam B. Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration. Retina. 2019;39:S2\u2013S8. https:\/\/doi.org\/10.1097\/IAE.0000000000002609. Suppl 1","journal-title":"Retina"},{"key":"294_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/sctm.18-0210","volume":"8","author":"B Scruggs","year":"2019","unstructured":"Scruggs B, Jiao C, Cranston C, Kaalberg E, Wang K, Russell S, et al. Optimizing donor cellular dissociation and subretinal injection parameters for stem cell-based treatments. Stem Cells Transl Med. 2019;8:797\u2013809. https:\/\/doi.org\/10.1002\/sctm.18-0210","journal-title":"Stem Cells Transl Med"},{"key":"294_CR8","doi-asserted-by":"publisher","first-page":"e0209996","DOI":"10.1371\/journal.pone.0209996","volume":"13","author":"K Takahashi","year":"2018","unstructured":"Takahashi K, Morizane Y, Hisatomi T, Tachibana T, Kimura S, Hosokawa M, et al. The influence of subretinal injection pressure on the microstructure of the monkey retina. PLoS One. 2018;13:e0209996. https:\/\/doi.org\/10.1371\/journal.pone.0209996","journal-title":"PLoS One"},{"key":"294_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/eye.2017.158","volume":"31","author":"K Xue","year":"2017","unstructured":"Xue K, Groppe M, Salvetti A, MacLaren R. Technique of retinal gene therapy: delivery of viral vector into the subretinal space. Eye. 2017;31:1308\u201316. https:\/\/doi.org\/10.1038\/eye.2017.158","journal-title":"Eye."},{"key":"294_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000479157","volume":"58","author":"Y Peng","year":"2017","unstructured":"Peng Y, Tang L, Zhou Y. Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res. 2017;58:217\u201326. https:\/\/doi.org\/10.1159\/000479157","journal-title":"Ophthalmic Res"},{"key":"294_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-020-00216-1","volume":"6","author":"H Vasconcelos","year":"2020","unstructured":"Vasconcelos H, Lujan B, Pennesi M, Yang P, Lauer A. Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery. Int J Retina Vitreous. 2020;6:13. https:\/\/doi.org\/10.1186\/s40942-020-00216-1","journal-title":"Int J Retina Vitreous"},{"issue":"Suppl 1","key":"294_CR12","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/IAE.0000000000001646","volume":"39","author":"N Gregori","year":"2019","unstructured":"Gregori N, Lam B, Davis J. Intraoperative use of microscope-integrated optical coherence tomography for subretinal gene therapy delivery. Retina. 2019;39 Suppl 1:S9\u2013S12. https:\/\/doi.org\/10.1097\/IAE.0000000000001646","journal-title":"Retina"},{"key":"294_CR13","doi-asserted-by":"publisher","unstructured":"Gange W, Sisk R, Besirli C, Lee T, Havunjian M, Schwartz H, et al. Perifoveal chorioretinal atrophy following subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber Congenital Amaurosis. Ophthalmol Retina. 2021;S2468-6530 00106-8. https:\/\/doi.org\/10.1016\/j.oret.2021.03.016","DOI":"10.1016\/j.oret.2021.03.016"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00294-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T03:05:03Z","timestamp":1677207903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00294-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":13,"journal-issue":{"issue":"10-11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["294"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00294-2","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AKL has received consulting fees or funds in support of clinical research from AGTC, Allergan, Atsena, Biogen, Cambridge Consulting, Genentech, IvericBio, Oxford BioMedic, Regenxbio, TeamedOn. MKP has received consulting fees from Adverum, AGTC, Allergan, Astellas Pharmaceuticals, Biogen, BlueRock, Editas, Iveric Bio, Novartis, Ora, RegenexBio, Roche, Viewpoint Therapeutics. MKP serves on the scientific advisor boards for Atsena, DTx Therapeutics, Endogena, Eyevensys, Horama, Nayan, Nacuity Pharmaceuticals, Ocugen, Sparing Vision, and Vedere. PY has received consulting fees from Adverum, AGTC, Nanoscope Therapeutics. All other authors declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Institutional Review Board approval at OHSU was obtained for review of all operative notes of patients receiving subretinal delivery of gene therapy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}